TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan

Core Viewpoint - TG Therapeutics Inc. is recognized as one of the best revenue growth stocks to consider for investment, with analysts maintaining positive ratings despite some adjustments in price targets [1][3]. Group 1: Analyst Ratings and Price Targets - JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 while keeping an Overweight rating on the shares [1]. - H.C. Wainwright analyst Emily Bodnar assigned a Buy rating, highlighting the company's strong commercial momentum and expected clinical catalysts in 2026 [3]. - TD Cowen analyst Tara Bancroft reiterated a Buy rating and set a price target of $50 for TG Therapeutics [3]. Group 2: Clinical Developments - TG Therapeutics presented trial results for its Briumvi treatment for relapsing multiple sclerosis at a medical forum in San Diego on February 6 [3]. - The anticipated clinical catalysts include results for consolidated IV dosing and a self-administered subcutaneous formulation for Briumvi, which could enhance its market share against competitors [3].